TNYA241220C5000
- 0.03
- 0.000.00%
Tenaya Therapeutics Newsroom
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $6 to $19
Tenaya Therapeutics Is Maintained at Buy by Chardan Capital
Tenaya Therapeutics Analyst Ratings
Cautious Optimism for Tenaya Therapeutics' TN-201: Early Phase Study Shows Promising Efficacy and Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Update: Tenaya Shares Sink After Readout of Heart Disease Therapy Shows Manageable Safety Profile
Tenaya Therapeutics Price Target Lowered to $6 From $8 at Leerink
Trending Stocks Today | Nukkleus Surges 871.22%
Crude Oil Down Over 1%; US Industrial Production Declines In November
Optimistic Outlook on Tenaya Therapeutics' TN-201 Gene Therapy for Hypertrophic Cardiomyopathy
Express News | Tenaya Therapeutics Inc : Leerink Partners Cuts Target Price to $6 From $8
Express News | Tenaya Therapeutics Shares Are Trading Lower. The Company Announced Data From the First Cohort of Patients in the MyPEAK-1 Clinical Trial of TN-201 Gene Therapy
Dow Dips Over 200 Points; US Retail Sales Top Estimates
Tenaya Therapeutics Reports Promising TN-201 Trial Results
Tenaya Therapeutics' Senior VP Resigns for New Opportunity
Express News | Tenaya Therapeutics Inc - Chihro Saito Resigns as Svp, Afo and Interim Pao of Tenaya
Tenaya Reports Early Results for Gene Therapy in Heart Disease
Express News | Tenaya Therapeutics Inc - Tn-201 Well Tolerated With Increasing Rna and Protein Levels
Tenaya Therapeutics To Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 Gene Therapy For MYBPC3-Associated Hypertrophic Cardiomyopathy On Dec. 17, 2024
Tenaya Therapeutics to Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024